Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paricalcitol in Renal Transplant Recipients with Secondary Hyperparathyroidism
NCT01220050Phase 2Completed
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Sep 2009
- Primary completion
- Jul 2012
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of paricalcitol in secondary hyperparathyroidism (SHPT) (2 arms), sponsored by Mario Negri Institute for Pharmacological Research. Primary endpoint: Parathyroid Hormone reduction at 6 months. Started Sep 2009; status: completed.
02
Drugs
paricalcitol
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT01220050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01220050.